α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of parkinson disease

NeuroToxicology

Volumn 32, Issue 5, 2011, Pages 622-629

  Covy, Jason P ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Synuclein; LRRK2; Manganese; Mutation; Parkinson disease; Toxicity

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; MANGANESE;

ARTICLE; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; GENE; GENE DUPLICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; LRRK2 GENE; MISSENSE MUTATION; MUTANT; NEUROTOXICITY; NONHUMAN; PARK8 GENE; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION;

AGING; ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; ANIMALS; CELL MEMBRANE; HUMANS; MANGANESE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 82455192353     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.01.003     Document Type: Article

References (136)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Albrecht M. LRRK2 mutations and parkinsonism. Lancet 2005, 365:1230.
3. Aschner M., Guilarte T.R., Schneider J.S., Zheng W. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol 2007, 221:131-147.
4. Au C., Benedetto A., Aschner M. Manganese transport in eukaryotes: the role of DMT1. Neurotoxicology 2008, 29:569-576.
5. Benedetto A., Au C., Aschner M. Manganese-induced dopaminergic neurodegeneration: insights into mechanisms and genetics shared with parkinson's disease. Chem Rev 2009, 109:4862-4884.
6. Benedetto A., Au C., Avila D.S., Milatovic D., Aschner M. Extracellular dopamine potentiates Mn-induced oxidative stress, lifespan reduction, and dopaminergic neurodegeneration in a BLI-3-dependent manner in Caenorhabditis elegans. PLoS Genet 2010, 6.
7. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006, 60:557-569.
8. Biskup S., West A.B. Zeroing in on LRRK2-linked pathogenic mechanisms in parkinson's disease. Biochim Biophys Acta 2009, 1792:625-633.
9. Braak H., Bohl J.R., Muller C.M., Rub U., de Vos R.A., Del T.K. Stanley Fahn lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic parkinson's disease reconsidered. Mov Disord 2006, 21:2042-2051.
10. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Sudhof T.C. α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
11. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIlwain K.L., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J Neurosci 2002, 22:8797-8807.
12. Cai T., Yao T., Zheng G., Chen Y., Du K., Cao Y., et al. Manganese induces the overexpression of α-synuclein in PC12 cells via ERK activation. Brain Res 2010, 1359:201-207.
13. Calne D.B., Peppard R.F. Aging of the nigrostriatal pathway in humans. Can J Neurol Sci 1987, 14:424-427.
14. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., Sudhof T.C. α-Synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
15. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., et al. α-Synuclein locus duplication as a cause of familial parkinson's disease. Lancet 2004, 364:1167-1169.
16. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset parkinson disease. Nat Med 1998, 4:1318-1320.
17. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000, 97:571-576.
18. Correia G.L., Ferreira J.J., Rosa M.M., Coelho M., Bonifati V., Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in parkinson's disease: a systematic review. Parkinsonism Relat Disord 2010, 16:237-242.
19. Courtneidge S.A. Activation of the pp60c-src kinase by middle T antigen binding or by dephosphorylation. EMBO J 1985, 4:1471-1477.
20. Covy J.P., Giasson B.I. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition. J Neurochem 2010, 115:36-46.
21. Cronford M.E., Chang L., Miller B.L. The neuropathology of parkinsonism-an overview. Brain Cogn 1995, 28:321-341.
22. Dachsel J.C., Farrer M.J. LRRK2 and parkinson disease. Arch Neurol 2010, 67:542-547.
23. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
24. Daniels A.J., Gysling K., Abarca J. Uptake and release of manganese by rat striatal slices. Biochem Pharmacol 1981, 30:1833-1837.
25. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998, 273:9443-9449.
26. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., Kim S.H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363:595-602.
27. Deng H., Le W., Guo Y., Hunter C.B., Xie W., Jankovic J. Genetic and clinical identification of parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005, 57:933-934.
28. Di Fonzo, Chien H.F., Socal M., Giraudo S., Tassorelli C., Iliceto G., et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset parkinson disease. Neurology 2007, 68:1557-1562.
29. Dick F.D., De P.G., Ahmadi A., Scott N.W., Prescott G.J., Bennett J., et al. Environmental risk factors for parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med 2007, 64:666-672.
30. Ding T.T., Lee S.J., Rochet J.C., Lansbury P.T. Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002, 41:10209-10217.
31. El-Agnaf O.M., Jakes R., Curran M.D., Middleton D., Ingenito R., Bianchi E., et al. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 1998, 440:71-75.
32. Elbaz A., Clavel J., Rathouz P.J., Moisan F., Galanaud J.P., Delemotte B., et al. Professional exposure to pesticides and parkinson disease. Ann Neurol 2009, 66:494-504.
33. Elberg G., Li J., Leibovitch A., Shechter Y. Non-receptor cytosolic protein tyrosine kinases from various rat tissues. Biochim Biophys Acta 1995, 1269:299-306.
34. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann Neurol 2004, 55:174-179.
35. Forman M.S., Lee V.M., Trojanowski J.Q. Nosology of parkinson's disease: looking for the way out of a quackmire. Neuron 2005, 47:479-482.
36. Forno L.S. Neuropathology of parkinson's disease. J Neuropathol Exp Neurol 1996, 55:259-272.
37. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005, 57:918-921.
38. Gaig C., Marti M.J., Ezquerra M., Rey M.J., Cardozo A., Tolosa E. G2019S LRRK2 mutation causing parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiat 2007, 78:626-628.
39. Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O., Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 2006, 59:714-719.
40. Gao H.M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q., Lee V.M. Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008, 28:7687-7698.
41. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for parkinson disease. Arch Neurol 1999, 56:33-39.
42. George J.M., Jin H., Woods W.S., Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995, 15:361-372.
43. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., et al. Biochemical and pathological characterization of LRRK2. Ann Neurol 2006, 59:315-322.
44. Giasson B.I., Lee V.M. Parkin and the molecular pathways of parkinson's disease. Neuron 2001, 31:885-888.
45. Giasson B.I., Lee V.M. Are ubiquitination pathways central to parkinson's disease?. Cell 2003, 114:1-8.
46. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M. Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999, 274:7619-7622.
47. Giasson B.I., Van Deerlin V.M. Mutations in LRRK2 as a cause of parkinson's disease. Neurosignals 2008, 16:99-105.
48. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., et al. A common LRRK2 mutation in idiopathic parkinson's disease. Lancet 2005, 365:415-416.
49. Gitler A.D., Chesi A., Geddie M.L., Strathearn K.E., Hamamichi S., Hill K.J., et al. α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009, 41:308-315.
50. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., et al. The parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006, 15:223-232.
51. Goedert M. α-Synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001, 2:492-501.
52. Goldberg M.S., Lansbury P.T. Is there a cause-and-effect relationship between α-synuclein fibrillization and parkinson's disease?. Nat Cell Biol 2000, 2:E115-E119.
53. Goldwurm S., Zini M., Mariani L., Tesei S., Miceli R., Sironi F., et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in parkinson disease. Neurology 2007, 68:1141-1143.
54. Greenbaum E.A., Graves C.L., Mishizen-Eberz A.J., Lupoli M.A., Lynch D.R., Englander S.W., et al. The E46K mutation in α-synuclein increases amyloid fibril formation. J Biol Chem 2005, 280:7800-7807.
55. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and parkinson's disease: three questions. ASN Neuro 2009, 1:13-24.
56. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006, 23:329-341.
57. Greten-Harrison B., Polydoro M., Morimoto-Tomita M., Diao L., Williams A.M., Nie E.H., et al. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci USA 2010, 107:19573-19578.
58. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52.
59. Hasegawa K., Kowa H. Autosomal dominant familial parkinson disease: older onset of age, and good response to levodopa therapy. Eur Neurol 1997, 38(Suppl 1):39-43.
60. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated parkinson's disease: a case-control study. Lancet Neurol 2008, 7:583-590.
61. Hernandez D.G., Paisan-Ruiz C., McInerney-Leo A., Jain S., Meyer-Lindenberg A., Evans E.W., et al. Clinical and positron emission tomography of parkinson's disease caused by LRRK2. Ann Neurol 2005, 57:453-456.
62. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., et al. Localization of parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 2007, 1155:208-219.
63. Higashi S., Moore D.J., Colebrooke R.E., Biskup S., Dawson V.L., Arai H., et al. Expression and localization of parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J Neurochem 2007, 100:368-381.
64. Higashi Y., Asanuma M., Miyazaki I., Hattori N., Mizuno Y., Ogawa N. Parkin attenuates manganese-induced dopaminergic cell death. J Neurochem 2004, 89:1490-1497.
65. Hirata Y., Kiuchi K., Nagatsu T. Manganese mimics the action of 1-methyl-4-phenylpyridinium ion, a dopaminergic neurotoxin, in rat striatal tissue slices. Neurosci Lett 2001, 311:53-56.
66. Ho C.C., Rideout H.J., Ribe E., Troy C.M., Dauer W.T. The parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 2009, 29:1011-1016.
67. Iaccarino C., Crosio C., Vitale C., Sanna G., Carri M.T., Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 2007, 16:1319-1326.
68. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
69. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994, 345:27-32.
70. Kachergus J., Mata I.F., Hulihan M., Taylor J.P., Lincoln S., Aasly J., et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005, 76:672-680.
71. Kannan N., Neuwald A.F. Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component?. J Mol Biol 2005, 351:956-972.
72. Karlsson R., Zheng J., Xuong N., Taylor S.S., Sowadski J.M. Structure of the mammalian catalytic subunit of cAMP-dependent protein kinase and an inhibitor peptide displays an open conformation. Acta Crystallogr D: Biol Crystallogr 1993, 49:381-388.
73. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
74. Kitazawa M., Anantharam V., Yang Y., Hirata Y., Kanthasamy A., Kanthasamy A.G. Activation of protein kinase C delta by proteolytic cleavage contributes to manganese-induced apoptosis in dopaminergic cells: protective role of Bcl-2. Biochem Pharmacol 2005, 69:133-146.
75. Knowles J.R. Enzyme-catalyzed phosphoryl transfer reactions. Annu Rev Biochem 1980, 49:877-919.
76. Koland J.G., Cerione R.A. Activation of the EGF receptor tyrosine kinase by divalent metal ions: comparison of holoreceptor and isolated kinase domain properties. Biochim Biophys Acta 1990, 1052:489-498.
77. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding α-synuclein in parkinson's disease. Nat Genet 1998, 18:106-108.
78. Lai B.C., Marion S.A., Teschke K., Tsui J.K. Occupational and environmental risk factors for parkinson's disease. Parkinsonism Relat Disord 2002, 8:297-309.
79. Latchoumycandane C., Anantharam V., Kitazawa M., Yang Y., Kanthasamy A., Kanthasamy A.G. Protein kinase Cdelta is a key downstream mediator of manganese-induced apoptosis in dopaminergic neuronal cells. J Pharmacol Exp Ther 2005, 313:46-55.
80. Lee B.D., Shin J.H., VanKampen J., Petrucelli L., West A.B., Ko H.S., et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of parkinson's disease. Nat Med 2010, 16:998-1000.
81. Lee E.J., Woo M.S., Moon P.G., Baek M.C., Choi I.Y., Kim W.K., et al. α-Synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010, 185:615-623.
82. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009, 18:R48-R59.
83. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A.L., Janin S., et al. LRRK2 G2019S as a cause of parkinson's disease in North African Arabs. N Engl J Med 2006, 354:422-423.
84. Lesage S., Ibanez P., Lohmann E., Pollak P., Tison F., Tazir M., et al. G2019S LRRK2 mutation in French and North African families with parkinson's disease. Ann Neurol 2005, 58:784-787.
85. Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M., et al. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 2006, 4:e144.
86. Li X., Tan Y.C., Poulose S., Olanow C.W., Huang X.Y., Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial parkinson's disease R1441C/G mutants. J Neurochem 2007, 103:238-247.
87. Li Y., Sun L., Cai T., Zhang Y., Lv S., Wang Y., et al. α-Synuclein overexpression during manganese-induced apoptosis in SH-SY5Y neuroblastoma cells. Brain Res Bull 2010, 81:428-433.
88. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by parkinson's-disease-related mutant α-synuclein. Neuron 2009, 64:807-827.
89. Lovitt B., Vanderporten E.C., Sheng Z., Zhu H., Drummond J., Liu Y. Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). Biochemistry 2010, 49:3092-3100.
90. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
91. Maekawa T., Kubo M., Yokoyama I., Ohta E., Obata F. Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen. Biochem Biophys Res Commun 2010, 392:431-435.
92. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in parkinson's disease: protein domains and functional insights. Trends Neurosci 2006, 29:286-293.
93. Melrose H., Lincoln S., Tyndall G., Dickson D., Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006, 139:791-794.
94. Melrose H.L., Kent C.B., Taylor J.P., Dachsel J.C., Hinkle K.M., Lincoln S.J., et al. A comparative analysis of leucine-rich repeat kinase 2 (LRRK2) expression in mouse brain and Lewy body disease. Neuroscience 2007, 147:1047-1058.
95. Moghal S., Rajput A.H., D'Arcy C., Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994, 13:175-178.
96. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000, 20:3214-3220.
97. Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S., Halter C.A., et al. Genetic screening for a single common LRRK2 mutation in familial parkinson's disease. Lancet 2005, 365:410-412.
98. Ning Y.P., Kanai K., Tomiyama H., Li Y., Funayama M., Yoshino H., et al. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 2008, 70:1491-1493.
99. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., et al. LRRK2 G2019S as a cause of parkinson's disease in Ashkenazi Jews. N Engl J Med 2006, 354:424-425.
100. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., et al. Cloning of the gene containing mutations that cause PARK8-linked parkinson's disease. Neuron 2004, 44:595-600.
101. Paisan-Ruiz C., Lang A.E., Kawarai T., Sato C., Salehi-Rad S., Fisman G.K., et al. LRRK2 gene in parkinson disease: mutation analysis and case control association study. Neurology 2005, 65:696-700.
102. Pakkenberg B., Moller A., Gundersen H.J., Mouritzen D.A., Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiat 1991, 54:30-33.
103. Perl D.P., Olanow C.W. The neuropathology of manganese-induced parkinsonism. J Neuropathol Exp Neurol 2007, 66:675-682.
104. Pifl C., Khorchide M., Kattinger A., Reither H., Hardy J., Hornykiewicz O. α-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter. Neurosci Lett 2004, 354:34-37.
105. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the α-synuclein gene identified in families with parkinson's disease. Science 1997, 276:2045-2047.
106. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001, 76:1265-1274.
107. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006, 38:1184-1191.
108. Roth J.A. Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination. Biol Res 2006, 39:45-57.
109. Roth J.A., Singleton S., Feng J., Garrick M., Paradkar P.N. Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. J Neurochem 2010, 113:454-464.
110. Schmidt K., Wolfe D.M., Stiller B., Pearce D.A. Cd2+, Mn2+, Ni2+ and Se2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochem Biophys Res Commun 2009, 383:198-202.
111. Simon-Sanchez J., Herranz-Perez V., Olucha-Bordonau F., Perez-Tur J. LRRK2 is expressed in areas affected by parkinson's disease in the adult mouse brain. Eur J Neurosci 2006, 23:659-666.
112. Simuni T., Hurtig H.I. Parkinson's disease: the clinical picture. Neurodegenerative dementias 2000, 193-203. McGraw-Hill, New York. C.M. Clark, J.Q. Trojanoswki (Eds.).
113. Singleton A., Gwinn-Hardy K. Parkinson's disease and dementia with Lewy bodies: a difference in dose?. Lancet 2004, 364:1105-1107.
114. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. α-Synuclein locus triplication causes parkinson's disease. Science 2003, 302:841.
115. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 2005, 102:18676-18681.
116. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. α-synuclein in Lewy bodies. Nature 1997, 388:839-840.
117. Squitti R., Gorgone G., Panetta V., Lucchini R., Bucossi S., Albini E., et al. Implications of metal exposure and liver function in parkinsonian patients resident in the vicinities of ferroalloy plants. J Neural Tran 2009, 116:1281-1287.
118. Su X., Federoff H.J., Maguire-Zeiss K.A. Mutant α-synuclein overexpression mediates early proinflammatory activity. Neurotox Res 2009, 16:238-254.
119. Sun G., Budde R.J. Requirement for an additional divalent metal cation to activate protein tyrosine kinases. Biochemistry 1997, 36:2139-2146.
120. Taylor S.S., Radzio-Andzelm E. Three protein kinase structures define a common motif. Structure 1994, 2:345-355.
121. Taymans J.M., Van den Haute C., Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 2006, 98:951-961.
122. Theodore S., Cao S., McLean P.J., Standaert D.G. Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of parkinson disease. J Neuropathol Exp Neurol 2008, 67:1149-1158.
123. Toru-Delbauffe D., Pierre M., Osty J., Chantoux F., Francon J. Properties of neurofilament protein kinase. Biochem J 1986, 235:283-289.
124. Uversky V.N. Neurotoxicant-induced animal models of parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 2004, 318:225-241.
125. Uversky V.N., Li J., Fink A.L. Evidence for a partially folded intermediate in α-synuclein fibril formation. J Biol Chem 2001, 276:10737-10744.
126. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. J Biol Chem 2001, 276:44284-44296.
127. Waxman E.A., Giasson B.I. Molecular mechanisms of α-synuclein neurodegeneration. Biochim Biophys Acta 2009, 1792:616-624.
128. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996, 35:13709-13715.
129. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005, 102:16842-16847.
130. Westerlund M., Hoffer B., Olson L. Parkinson's disease: exit toxins, enter genetics. Prog Neurobiol 2010, 90:146-156.
131. Withers G.S., George J.M., Banker G.A., Clayton D.F. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res 1997, 99:87-94.
132. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., Biere A.L. α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of parkinson's disease. J Biol Chem 1999, 274:19509-19512.
133. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., et al. The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-173.
134. Zhang P., Lokuta K.M., Turner D.E., Liu B. Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia. J Neurochem 2010, 112:434-443.
135. Zhang P., Wong T.A., Lokuta K.M., Turner D.E., Vujisic K., Liu B. Microglia enhance manganese chloride-induced dopaminergic neurodegeneration: role of free radical generation. Exp Neurol 2009, 217:219-230.
136. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.